**WHAT IS CLAIMED IS:**

1. Use of a therapeutically effective amount of an anti-IL-6 antibody in the manufacture of a medicament for treating cardiovascular disease in a subject, wherein the subject has at least one copy of the *TMPRSS6* rs855791 major allele.

2. The use of claim 1, wherein the  wherein the therapeutically effective amount of the anti-IL-6 antibody is an amount effective to reduce the risk of cardiovascular mortality.

3. The use of claim 1 or 2, wherein the subject has chronic kidney disease.

4. The use of claim 3, wherein the subject has KDOQI stage 1 chronic kidney disease.

5. The use of claim 3, wherein the subject has KDOQI stage 2 chronic kidney disease.

6. The use of claim 3, wherein the subject has KDOQI stage 3 chronic kidney disease.

7. The use of claim 3, wherein the subject has KDOQI stage 4 chronic kidney disease.

8. The use of claim 3, wherein the subject has KDOQI stage 5 chronic kidney disease.

9. The use of claim 1, 2 or 3, wherein the subject has inflammation.

10. The use of claim 9, wherein the inflammation in the subject is characterized by elevated levels of serum IL-6 and/or CRP relative to a reference level.

11. The use of claim 9, wherein the therapeutically effective amount of the anti-IL-6 antibody is an amount effective to neutralize inflammation.

12. The use of claim 9, wherein the subject has a pre-treatment CRP level greater than 2 mg/ml.

13. The use of claim 1, 2, 3 or 9, wherein the subject has pre-treatment serum IL-6 of greater than 2.5 pg/ml/

14. The use of claim 1, wherein the therapeutically effective amount of the anti-IL-6 antibody is an amount effective to reduce the risk of heart failure.

15. The use of any of the preceding claims, wherein the anti-IL-6 antibody comprises all six variable region CDRs of MEDI5117.

16. The use of claim 15, wherein the anti-IL-6 antibody comprises the VH and VL of MEDI5117.

17. The use of claim 16, wherein the anti-IL-6 antibody is MEDI5117.

18. The use of claim 2, wherein the subject has inflammation and chronic kidney disease, and the anti-IL-6 antibody is MEDI5117.